Nirogacestat
Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers[1].
Product Specifications
CAS Number
1290543-63-3
Product Name Alternative
PF-3084014
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; γ-secretase
Type
Reference compound
Related Pathways
Apoptosis; Neuronal Signaling; Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PF-3084014.html
Purity
99.83
Solubility
DMSO : 28.57 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
FC1=C2C(CC[C@H](N[C@@H](CCC)C(NC3=CN(C(C)(C)CNCC(C)(C)C)C=N3)=O)C2)=CC(F)=C1
Molecular Formula
C27H41F2N5O
Molecular Weight
489.64
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
EGLN1 / PHD2 (366G/76/3), CF647 conjugate, 0.1mg/mL
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2744), CF568 conjugate, 0.1mg/mL
Alpha 1 microglobuLin (AMBP) (NM_001633) Human Recombinant Protein
